Conference tag line

It was great spending time with pharma colleagues who have similar issues and challenges.

• Why oncology market access models must evolve

  The proliferation of stakeholders makes oncology market access increasingly complex—and successful models increasingly essential. Peter Mansell reports.

  read more

  9:59am, 7th Sep 2010
• Comprehensive strategies for market access

  Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.

  read more

  9:51am, 7th Sep 2010
• Market access: Risk sharing and alternative pricing schemes

  Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one.

  read more

  2:33pm, 10th Aug 2010